Prostate-Specific Antigen, Total

Cleveland HeartLab Cancer, P, Test

CPT Code:

Prostate-Specific Antigen, Total: 84153
Prostate-Specific Antigen, Total with reflex to Prostate-Specific Antigen, Free: If Total PSA is >4.000 ng/mL and <10.000 ng/mL, then PSA Free will be performed at an additional charge (CPT code: 84154).

Order Code:

Prostate-Specific Antigen, Total: C154
Prostate-Specific Antigen, Total with reflex to Prostate-Specific Antigen, Free: C512
ABN Requirement:  No
Synonyms: PSA; TPSA
Specimen: Serum
Volume: 0.5 mL
Minimum Volume: 0.2 mL
Container: Gel-barrier tube (SST, Tiger Top)


  1. Collect and label sample according to standard protocols.
  2. Gently invert tube 5 times immediately after draw. DO NOT SHAKE.
  3. Allow blood to clot 30 minutes.
  4. Centrifuge for 10 minutes.

Special Instructions: Samples should not be taken from patients receiving therapy with high biotin doses (>5 mg/day) until at least 8 hours following the last dose. Samples should be collected prior to a patient receiving a digital rectal exam.

Transport: Store serum at 2°C to 8°C after collection and ship the same day per packaging instructions provided with the Cleveland HeartLab shipping box.


Ambient (15-25°C): not acceptable
Refrigerated (2-8°C): 5 days
Frozen (-20°C): 6 months
Deep Frozen (-70°C): 6 months

Causes for Rejection: Samples which are heat-inactivated; specimens other than serum; improper labeling; samples not stored properly; samples older than stability limits

Methodology: Electrochemiluminescence Immunoassay (ECLIA)

Turn Around Time: 1 to 3 days

Reference Range:

Age ng/mL
All Ages ≤4.000

An interpretive comment is also attached to each result:


Test Method: Roche Chemiluminescent Immunoassay:

<1.0 ng/mL TPSA: 8.8% Risk for Prostate Cancer

1.1-2.0 ng/mL TPSA: 17.8% Risk for Prostate Cancer

2.1-3.0 ng/mL TPSA: 23.9% Risk for Prostate Cancer

3.1-4.0 ng/mL TPSA: 26.9% Risk for Prostate Cancer

4.1-10.0 ng/mL TPSA: >27% Risk for Prostate Cancer

>10.0 ng/mL TPSA: >50% Risk for Prostate Cancer

Thompson et al. New Engl J Med. 2004;350:2239

Presti et al. J Urol. 2003;169:125

Use: The total PSA test is used for the evaluation and monitoring of patients with prostatic carcinoma.

Limitations: In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur.

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.